Clinical Trial Update: Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CD19/CD22 CAR-T cells in children and young adults with recurrent or refractory B-cell acute lymphoblastic leukemia; the trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Childhood B-cell Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19/CD22 CAR-T cells

Snippet

Sponsor: Stanford University | Conditions: B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Status: ACTIVE_NOT_RECRUITING